On-Demand Webinar: Developing liquid formulations for the oral dosing of lipophilic drugs

Pace® Life Sciences has decades of practical formulation development experience and expertise with sterile and non-sterile products, oral or topical dosages. Our attention to detail helps us create an appropriate formulation for your drug product that is safe, pure, and effective. Our formulation strategies will withstand FDA scrutiny and accelerate the successful commercialization and launch of your product.

Sterile products include injectable solutions, suspensions, emulsions, gels, and lyophilized powders.

Non-sterile products include tablets, capsules, solutions, suspensions, and semi-solids.

Contact Pace® today about your formulation needs.

Our team approaches each formulation project with the eventual commercial product in mind. We specialize in developing effective and robust pharmaceutical formulations that are:

Effectively preserve the active pharmaceutical ingredient (API) and control the delivery through the intended route of administration.

Meet the unique requirements to ensure the product is safe, tolerable to the patient, and comfortable at the site of administration by controlling key variables.

Compatible with technologies and processes within Pace® Life Sciences, and scalable to a wide range of standard processes available within commercial contract manufacturing organizations (CMOs).

Chemically & Physically Stable
Effectively preserve the API throughout the manufacturing process, distribution, product shelf life, and administration.

Pharmaceutical Formulation Development Services

Excipient Compatibility Studies
Our experience with a wide range of dosage forms helps our clients develop formulations that work within the clinic and withstand the increased rigor of today’s regulated environment.

Formulation Studies
Quality by design (QbD) studies are developed with attention to every detail from the use of Generally Recognized as Safe (GRAS) ingredients, to the identification of potential stability problems, compatibility with container/closure systems and stability of the API under the conditions of pharmaceutical manufacturing.